The United States Supreme Court has ruled that mifepristone, one of the two drugs used in medication abortion, may continue to be prescribed via telehealth and delivered by mail. The decision, issued on 14 May 2026, overturns a temporary nationwide ban on such access imposed by a federal appellate court on 1 May. The ruling is temporary, however, and the legal battle is far from over.

The case was brought by Louisiana, a southern US state that has banned abortion entirely since the Supreme Court's landmark 2022 Dobbs ruling overturned the constitutional right to an abortion. Louisiana argued that the Biden administration's expansion of telehealth prescribing for mifepristone was politically motivated and that mailing the pill violated the Comstock Act — an 1873 federal law that criminalises the mailing of materials related to abortion, though it has rarely been enforced. The 5th US Circuit Court of Appeals agreed that Louisiana would likely prevail, and on 1 May suspended the FDA regulation permitting telehealth prescriptions nationwide. After mifepristone's manufacturers appealed, the Supreme Court issued a short-term stay and ultimately voted on 14 May to keep the FDA rule in place while lower courts continue their review. Justices Samuel Alito and Clarence Thomas dissented, with Alito accusing the majority of undermining the Dobbs ruling and Thomas arguing that the Comstock Act prohibits mailing the drug.

The stakes are considerable. Since 2023, nearly two-thirds of all abortions in the United States have involved mifepristone, and by late 2024 one in four abortions was carried out using pills obtained through telehealth. Since the Dobbs ruling, 13 of the country's 50 states have imposed total abortion bans, yet overall abortion numbers have not fallen — in part because women in ban states have been obtaining pills by mail from providers in states where abortion remains legal. By June 2025, telehealth abortions had risen fivefold compared to before Dobbs, with more than half occurring in ban states. Louisiana's attorney general described this as an "organised and dangerous system" for distributing drugs.

The Supreme Court's intervention does not resolve the underlying legal questions. The case returns to the 5th Circuit, which has signalled it is inclined to rule that the FDA exceeded its authority in allowing telehealth prescribing. Should that court strike down the regulation — or should the FDA itself rescind it — mifepristone would be unavailable by mail in all 50 states, not only those with outright bans. That would affect not just women in ban states, but also those in low-income, rural, or otherwise underserved communities where in-person reproductive healthcare is difficult to access. A final ruling from the Supreme Court may ultimately be required to settle the matter.

The drug at the centre of the dispute has a well-documented safety record: first approved in France in 1988 and in the United States in 2000, mifepristone has been found in studies to be as safe as common over-the-counter medications. Its legal vulnerability, however, stems less from questions of medical science than from the broader political and legal transformation of abortion rights in the United States since 2022 — a transformation whose consequences are still being contested in courts across the country.